Cargando…
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
BACKGROUND: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outco...
Autores principales: | Kooistra, Emma J., Waalders, Nicole J. B., Grondman, Inge, Janssen, Nico A. F., de Nooijer, Aline H., Netea, Mihai G., van de Veerdonk, Frank L., Ewalds, Esther, van der Hoeven, Johannes G., Kox, Matthijs, Pickkers, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726611/ https://www.ncbi.nlm.nih.gov/pubmed/33302991 http://dx.doi.org/10.1186/s13054-020-03364-w |
Ejemplares similares
-
A higher BMI is not associated with a different immune response and disease course in critically ill COVID-19 patients
por: Kooistra, Emma J., et al.
Publicado: (2021) -
Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020) -
Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19
por: de Nooijer, Aline H., et al.
Publicado: (2021) -
THE ROLE OF OBESITY AND PLASMA ADIPOCYTOKINES IN IMMUNE DYSREGULATION IN SEPSIS PATIENTS
por: de Nooijer, Aline H., et al.
Publicado: (2023) -
Increased Plasma Heparanase Activity in COVID-19 Patients
por: Buijsers, Baranca, et al.
Publicado: (2020)